Back to Search Start Over

Melatonin: Pharmacology, Functions and Therapeutic Benefits

Authors :
Annaëlle Charrier
Eric Bellissant
Claire Fougerou
Nemat Jaafari
Sylvie Tordjman
Richard Delorme
Sylvie Chokron
Service Psychiatrie de l'Enfant et de l'Adolescent
CHU Pontchaillou [Rennes]-Centre Hospitalier Guillaume Régnier [Rennes]-CHS (Centre Hospitalier Spécialisé lutte Maladies Mentales)
Laboratoire Psychologie de la Perception (LPP - UMR 8242)
Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS)
Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Robert Debré
Centre d'Investigation Clinique [Rennes] (CIC)
Université de Rennes 1 (UR1)
Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
Service de Pharmacologie
CHU Pontchaillou [Rennes]
CIC - Poitiers
Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Laboratoire de neurosciences expérimentales et cliniques (LNEC)
Université de Poitiers-Institut National de la Santé et de la Recherche Médicale (INSERM)
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré
Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
Service de Pharmacologie [Rennes]
Laboratoire Psychologie de la Perception ( LPP - UMR 8242 )
Université Paris Descartes - Paris 5 ( UPD5 ) -Centre National de la Recherche Scientifique ( CNRS )
Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré
Centre d'Investigation Clinique [Rennes] ( CIC )
Université de Rennes 1 ( UR1 )
Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale ( INSERM )
Université de Poitiers-Centre hospitalier universitaire de Poitiers ( CHU Poitiers ) -Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM )
Laboratoire de neurosciences expérimentales et cliniques ( LNEC )
Université de Poitiers-Institut National de la Santé et de la Recherche Médicale ( INSERM )
Source :
Current Neuropharmacology, Current Neuropharmacology, Bentham Science Publishers, 2017, 15 (3), pp.434--443. ⟨10.2174/1570159X14666161228122115⟩, Current Neuropharmacology, 2017, 15 (3), pp.434--443. ⟨10.2174/1570159X14666161228122115⟩, Current Neuropharmacology, Bentham Science Publishers, 2017, 15 (3), pp.434--443. 〈10.2174/1570159X14666161228122115〉
Publication Year :
2017
Publisher :
HAL CCSD, 2017.

Abstract

International audience; Background: Melatonin synchronizes central but also peripheral oscillators (fetal adrenal gland, pancreas, liver, kidney, heart, lung, fat, gut, etc.), allowing temporal organization of biological functions through circadian rhythms (24-hour cycles) in relation to periodic environmental changes and therefore adaptation of the individual to his/her internal and external environment. Measures of melatonin are considered the best peripheral indices of human circadian timing based on an internal 24-hour clock. Methods: First, the pharmacology of melatonin (biosynthesis and circadian rhythms, pharmacokinetics and mechanisms of action) is described, allowing a better understanding of the short and long term effects of melatonin following its immediate or prolonged release. Then, research related to the physiological effects of melatonin is reviewed. Results: The physiological effects of melatonin are various and include detoxification of free radicals and antioxidant actions, bone formation and protection, reproduction, and cardiovascular, immune or body mass regulation. Also, protective and therapeutic effects of melatonin are reported, especially with regard to brain or gastrointestinal protection, psychiatric disorders, cardiovascular diseases and oncostatic effects. Conclusion: This review highlights the high number and diversity of major melatonin effects and opens important perspectives for measuring melatonin as a biomarker (biomarker of early identification of certain disorders and also biomarker of their follow-up) and using melatonin with clinical preventive and therapeutic applications in newborns, children and adults based on its physiological regulatory effects.

Details

Language :
English
ISSN :
1570159X
Database :
OpenAIRE
Journal :
Current Neuropharmacology, Current Neuropharmacology, Bentham Science Publishers, 2017, 15 (3), pp.434--443. ⟨10.2174/1570159X14666161228122115⟩, Current Neuropharmacology, 2017, 15 (3), pp.434--443. ⟨10.2174/1570159X14666161228122115⟩, Current Neuropharmacology, Bentham Science Publishers, 2017, 15 (3), pp.434--443. 〈10.2174/1570159X14666161228122115〉
Accession number :
edsair.doi.dedup.....bcd949d4d943764447dabc1be9fcd36d